BR9908202A - Dispersão lipossomal de eritropoietina - Google Patents

Dispersão lipossomal de eritropoietina

Info

Publication number
BR9908202A
BR9908202A BR9908202-0A BR9908202A BR9908202A BR 9908202 A BR9908202 A BR 9908202A BR 9908202 A BR9908202 A BR 9908202A BR 9908202 A BR9908202 A BR 9908202A
Authority
BR
Brazil
Prior art keywords
erythropoietin
cholesterol
liposome
liposomal dispersion
lecithin
Prior art date
Application number
BR9908202-0A
Other languages
English (en)
Inventor
Rainer Naeff
Sandro Delmenico
Andre Wetter
Frank-Ulrich Floether
Original Assignee
Cilac Ag Internat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilac Ag Internat filed Critical Cilac Ag Internat
Publication of BR9908202A publication Critical patent/BR9908202A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

Patente de Invenção: <B>"DISPERSãO LIPOSSOMAL DE ERITROPOIETINA"<D>. A presente invenção refere-se a uma formulação com base em lipossoma de eritropoietina compreendendo: (a) uma quantidade eficaz de uma eritropoietina; (b) uma fase lipídica compreendendo: (i) lecitina ou lecitina hidrogenada; (ii) opcionalmente, um composto de lipídeo eletropositivo ou eletronegativo carregado; e (iii) colesterol ou um derivado deste selecionado dos ésteres de colesterol, derivados de glicol de polietileno de colesterol (PEG-colesteróis), e derivados de ácido orgânico de colesteróis; e (c) um tampão de fosfato. A forma dosagem parenteral com base em lipossoma da invenção é preparada por meio de uma técnica de injeção de etanol. A composição evita a necessidade para uso de albumina de soro humano e apresenta estabilidade superior.
BR9908202-0A 1998-02-23 1999-02-12 Dispersão lipossomal de eritropoietina BR9908202A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98103111A EP0937456B1 (en) 1998-02-23 1998-02-23 Erythropoietin liposomal dispersion
PCT/IB1999/000249 WO1999042085A1 (en) 1998-02-23 1999-02-12 Erythropoietin liposomal dispersion

Publications (1)

Publication Number Publication Date
BR9908202A true BR9908202A (pt) 2000-10-24

Family

ID=8231466

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908202-0A BR9908202A (pt) 1998-02-23 1999-02-12 Dispersão lipossomal de eritropoietina

Country Status (23)

Country Link
US (2) US6645522B2 (pt)
EP (1) EP0937456B1 (pt)
JP (1) JP4613294B2 (pt)
KR (1) KR100591871B1 (pt)
CN (1) CN1184958C (pt)
AT (1) ATE271376T1 (pt)
AU (1) AU750481B2 (pt)
BR (1) BR9908202A (pt)
CA (1) CA2320072C (pt)
CZ (1) CZ296415B6 (pt)
DE (1) DE69825137T2 (pt)
DK (1) DK0937456T3 (pt)
ES (1) ES2224299T3 (pt)
HU (1) HUP0101026A2 (pt)
IL (2) IL137808A0 (pt)
NO (1) NO20004186L (pt)
NZ (1) NZ506429A (pt)
PL (1) PL194502B1 (pt)
PT (1) PT937456E (pt)
RU (1) RU2218914C2 (pt)
SI (1) SI0937456T1 (pt)
SK (1) SK284036B6 (pt)
WO (1) WO1999042085A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0937456B1 (en) * 1998-02-23 2004-07-21 Cilag AG International Erythropoietin liposomal dispersion
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
EP1111050B1 (de) * 1999-12-22 2007-03-14 Dade Behring Marburg GmbH Lösungen von humanem Procalcitonin
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
JP2004115397A (ja) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd 血管疾患治療薬を含むリポソーム
EP1592416B1 (en) * 2003-02-07 2009-01-07 ProMetic BioSciences Inc. Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
CN1822844B (zh) * 2003-07-17 2012-05-09 大塚制药株式会社 含配糖物的脂质体
JP2007517769A (ja) * 2003-09-29 2007-07-05 ウォーレン ファーマシューティカルズ，インコーポレーテッド 敗血症および癒着形成の治療および予防のための組織保護性サイトカイン
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
CN100508953C (zh) * 2004-05-24 2009-07-08 波利门科学生物免疫研究有限公司 用于药物释放的过载脂质体
KR100684380B1 (ko) 2005-05-24 2007-02-20 한국화학연구원 빗살형 폴리에틸렌글리콜을 결합한 리포솜 및 이의 제조방법
US9119782B2 (en) 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
US20100310636A1 (en) * 2007-05-09 2010-12-09 Gita Sharma Stearically stabilized unilamilar vesicles, process for preparation thereof and use thereof
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
WO2011162818A2 (en) * 2010-06-23 2011-12-29 Controlled Nanovolumes, Inc. Lecithin carrier vesicles and methods of making the same
EA018472B1 (ru) * 2010-09-15 2013-08-30 Открытое Акционерное Общество "Протек" Частицы, содержащие эритропоэтин, для лечения и профилактики неврологических и гематологических заболеваний и нарушений
AU2014236559B2 (en) 2013-03-14 2020-03-12 Julie HUGHES Cholestosome vesicles for incorporation of molecules into chylomicrons
CN103751214A (zh) * 2014-01-03 2014-04-30 广州市鼍龙生物技术开发有限公司 一种鳄鱼油纳米脂质体及其制备方法
WO2015166988A1 (ja) * 2014-04-30 2015-11-05 富士フイルム株式会社 リポソームの製造方法
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
AU598002B2 (en) * 1986-07-15 1990-06-14 Cilag Ltd. Method of preparing single bilayered liposomes
JPH087219B2 (ja) 1992-04-27 1996-01-29 雪印乳業株式会社 リポソーム封入生理活性蛋白質の定量方法
JPH06228012A (ja) 1993-01-29 1994-08-16 Dai Ichi Seiyaku Co Ltd リポソーム製剤
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
HUT72326A (en) * 1993-10-06 1996-04-29 Amgen Inc Stable protein phospholipid compositions and methods
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
JP3850468B2 (ja) * 1994-12-28 2006-11-29 中外製薬株式会社 エリスロポエチンのリポソーム製剤
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
EP0937456B1 (en) * 1998-02-23 2004-07-21 Cilag AG International Erythropoietin liposomal dispersion

Also Published As

Publication number Publication date
DE69825137D1 (de) 2004-08-26
CN1298296A (zh) 2001-06-06
DK0937456T3 (da) 2004-11-08
SI0937456T1 (en) 2004-12-31
EP0937456B1 (en) 2004-07-21
KR100591871B1 (ko) 2006-06-23
US20040052838A1 (en) 2004-03-18
PT937456E (pt) 2004-10-29
RU2218914C2 (ru) 2003-12-20
IL137808A0 (en) 2001-10-31
NZ506429A (en) 2003-03-28
NO20004186D0 (no) 2000-08-22
AU2180899A (en) 1999-09-06
ES2224299T3 (es) 2005-03-01
ATE271376T1 (de) 2004-08-15
NO20004186L (no) 2000-08-22
JP2002503685A (ja) 2002-02-05
CA2320072A1 (en) 1999-08-26
CZ296415B6 (cs) 2006-03-15
US6645522B2 (en) 2003-11-11
IL137808A (en) 2007-07-24
CA2320072C (en) 2009-04-07
JP4613294B2 (ja) 2011-01-12
WO1999042085A1 (en) 1999-08-26
CN1184958C (zh) 2005-01-19
KR20010041152A (ko) 2001-05-15
DE69825137T2 (de) 2005-07-21
SK284036B6 (sk) 2004-08-03
SK12222000A3 (sk) 2001-11-06
CZ20002959A3 (cs) 2001-10-17
US20020028236A1 (en) 2002-03-07
AU750481B2 (en) 2002-07-18
HUP0101026A2 (hu) 2001-08-28
PL194502B1 (pl) 2007-06-29
EP0937456A1 (en) 1999-08-25
PL342514A1 (en) 2001-06-18

Similar Documents

Publication Publication Date Title
CA2320072A1 (en) Erythropoietin liposomal dispersion
MY111841A (en) Injectable liposomal pharmaceutical preparations
NZ212577A (en) Topical anti-inflammatory compositions containing naphthalene derivatives
AU2001260414A1 (en) Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
KR970706021A (ko) N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS)
ATE308327T1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
KR960703598A (ko) 신경 질환 치료제(agent for curing neurotic diseases)
BR9913810A (pt) 4-carboxiamino-1,2,3,4-tetrahidroquinolinas substituìdas em posição 2 como inibidores de cetp
AU1438699A (en) Fatty acid uninterrupted by a methylene as anti-inflammatory agents in superficial tissues of mammals
BR9911013A (pt) Derivados de pirazol como inibidores da p-38 map quinase
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
TR200002159T2 (tr) NSAI ilaçların verilmesi için topikal bileşimler.
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
HUP9901319A2 (hu) 9-Hidroxi-riszperidon zsírsavészterek vizes szuszpenziói, előállításuk és alkalmazásuk
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
BR0009765B1 (pt) Compostos de ésteres de l-carnitina ou alcanoil l-carnitinase, uso dos mesmos, lipossomas contendo os referidos compostos e composições farmacêuticas e cosméticas contendo os ditos lipossomas.
RU2000124317A (ru) Эритропоэтиновая липосомальная дисперсия
ES2124477T3 (es) Uso de un fosfato de ascorbilo y tocoferilo para la preparacion de un medicamento para el tratamiento de la pancreatitis.
HUP9801712A2 (hu) Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
BR9714047A (pt) Derivados de ácido carboxìlico, uso dos mesmos, combinação destes com um ou mais compostos ativos, preparação de drogas para a administração oral e parenteral, e, antagonista de receptor de endotelina
BR0312004A (pt) Composições de aerossol transdérmicas
EP0633021B1 (en) Chondroprotective agents
DE69809435D1 (de) Inhibitor- und konservierungsmittelzusammensetzung
WO2001041706A3 (en) Lipid nanotubules for topical delivery

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]